Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg
暂无分享,去创建一个
R. Labianca | D. Kerr | W. Scheithauer | T. Conroy | P. Therasse | E. Van Cutsem | B. Nordlinger | M. Ducreux | P. Rougier | D. Cunningham | D. Nitti | Jeff Evans | J. Blazeby | B. Glimelius | S. Ahmedzai | D. Curran | H. Schmoll | E. Díaz-Rubio | A. Sobrero | G. Blijham | T. Sahmoud | G. Kiebert | H. Bleiberg | J. Wils | G. Hutchinson | H. Köhne | R. Langendijk | T. Wagener | J. Wilke | A. Marinus | J. Evans
[1] W. Scheithauer,et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. , 1998, British Journal of Cancer.
[2] M. Ducreux,et al. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. , 1997, European Journal of Cancer.
[3] C. Köhne,et al. The identification of high risk patients with metastatic colorectal cancer , 1997 .
[4] A. Padhani,et al. 1097 – A prospective randomlsed trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer , 1997 .
[5] R. Goldberg,et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Bleiberg. Colorectal cancer--is there an alternative to 5-FU? , 1997, European journal of cancer.
[8] W. Scheithauer,et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Barni,et al. High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study , 1997 .
[10] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Tournigand,et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.
[12] S. Culine,et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Bertino,et al. Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M Buyse,et al. On the relationship between response to treatment and survival time. , 1996, Statistics in medicine.
[15] D. Kerr,et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] L. Fallowfield. Quality of quality-of-life data , 1996, The Lancet.
[17] L. Collette,et al. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Michaelis,et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. V. Von Hoff,et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] I. Seymour,et al. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Thomas J. Smith,et al. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Cutsem. A Glimpse of the Future. New Directions in the Treatment of Colorectal Cancer , 1996 .
[23] C. Stoffregen,et al. Weekly High-Dose 5-Fluorouracil 24-Hour Infusion and Intermediate-Dose Folinic Acid Bolus in Metastatic Colorectal Cancer , 1996 .
[24] M. Ychou,et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] D. Grignon,et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. , 1995, Archives of pathology & laboratory medicine.
[26] L. Fielding,et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Colorectal Cancer Working Group. , 1995, Archives of pathology & laboratory medicine.
[27] S. Brienza,et al. 933 Oxaliplatin (L-OHP®): Global safety in 682 patients (PTS) , 1995 .
[28] D. Kerr,et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. , 1995, European journal of cancer.
[29] D. Alderson,et al. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] A. Norman,et al. The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer , 1995 .
[31] T. Fleming,et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Fairclough,et al. Comparison of Time-tradeoff Utilities and Rating Scale Values of Cancer Patients and Their Relatives , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.
[33] W. Hiddemann,et al. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] C. Marsault,et al. A Randomized Study of Bolus Fluorouracil Plus Folinic Acid Versus 21‐Day Fluorouracil Infusion Alone or in Association with Cyclophosphamide and Mitomycin C in Advanced Colorectal Carcinoma , 1995, American journal of clinical oncology.
[35] C. Tangen,et al. Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.
[36] A. Norman,et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] N. Petrelli,et al. Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial , 1995, Cancer.
[38] K. Abrams,et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases , 1994, The Lancet.
[39] F. Lévi,et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.
[40] J. Ajani,et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] L. Påhlman,et al. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. , 1994, British Journal of Cancer.
[42] W. Scheithauer,et al. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer , 1994, Cancer.
[43] L. Påhlman,et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer , 1994, Cancer.
[44] A. Oxman,et al. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] W. Scheithauer,et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.
[46] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[47] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] B. Meyerowitz. Quality of life in breast cancer patients: the contribution of data to the care of patients. , 1993, European journal of cancer.
[49] H. Schmoll,et al. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. , 1992, Seminars in oncology.
[50] J. Wils. High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? , 1992, Seminars in oncology.
[51] P. Piedbois. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] S. Barni,et al. Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] K. Westbrook,et al. Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence. , 1991, Archives of surgery.
[54] J. de Haes,et al. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. , 1990, British Journal of Cancer.
[55] D. Tulsky,et al. Measuring quality of life today: methodological aspects. , 1990, Oncology.
[56] L. Påhlman,et al. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens. , 1989, European journal of cancer & clinical oncology.
[57] J G Fryer,et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] A. Howell,et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. , 1988, European journal of cancer & clinical oncology.
[59] G. Torrance. Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.
[60] R. Temple,et al. Food and Drug Administration requirements for approval of new anticancer drugs. , 1985, Cancer treatment reports.
[61] A McMurray,et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] K C Cain,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.